<![CDATA[ABSTRACTThe goal of palliative care is to increase the quality of life and to reduce the symptomp, but it often increases the complexity of patients therapy. The aim of this study is to evaluate prevalance, the risk factor, and the profile of Drug Related Problems (DRPs) from the palliative therapy patient who suffer from solid cancer at Dharmais Hospital National Cancer Center. This is a cross sectional study and the data was taken from the patients medical records starting from March to June 2011. The patient characteristics who followed this study were 33 patients women (68.8%), and the frequent cases of solid cancer was breast cancer, i.e about 15 patients (31.3%). Most of the patients (64.6%) were in palliative care. Adverse reactions occurred in 70.1% patienst and 66.2% patients got potential adverse reaction. Only 5.7% drug-drug interactions were detected with moderate significance. About 15.0% drug interactions caused by the use of morphine, and amitriptyline at the same time. The risk of incident adverse reactions were influenced by age, sex,history of curative chemotherapy regimen, comorbidities, and the number of drug use. The increasing risk of drug interaction incident was the influenced by the number of drugs using ( > 5 drugs) and if the patient had a comorbidities. Most of patients in the palliative care would get the DRP but drug interactions did not always occur.ABSTRAKTerapi paliatif bertujuan meningkatkan kualitas hidup dan mengurangi gejala, namun akan menambah kompleksitas terapi. Penelitian ini bertujuan mengevaluasi prevalensi, faktor risiko, dan profil kejadian Drug Related Problems (DRPs) terapi paliatif pasien kanker padat stadium lanjut. Penelitian ini adalah penelitian potong lintang. Dan data diambil dari rekam medis pasien bulan Maret Juni 2011. Karakteristik pasien, 33 orang (68,8%) perempuan, dan kasus kanker padat terbesar adalah kanker payudara sebanyak 15 orang (33,3%). Sebagian besar pasien kanker padat stadium lanjut (64,6%) hanya menjalani satu kali terapi paliatif. Reaksi obat yang tidak diinginkan (ROTD) termanifestasi dialami 70,1% subyek uji dan 66,2% uji berpotensi mengalami ROTD. Interaksi obat dengan signifikansi moderate ditemui pada 5,7% terapi pasien. Sebesar 15,0% interaksi tersebut akibat penggunaan morfin dan amitriptilin bersama. Risiko ROTD meningkat karena usia, jenis kelamin, riwayat pemberian regimen kemoterapi kuratif, penyakit penyerta, dan jumlah obat yang digunakan. Peningkatan risiko kejadian interaksi obat dipengaruhi oleh penggunaan > 5 jenis obat dan adanya penyakit penyerta. Pasien kanker padat stadium lanjut yang menjalani terapi paliatif pada umumnya mengalami ROTD, namun jarang ditemukan interaksi obat.]]>
Copyrights © 2015
